Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cell

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 721-727

  Tachiwada, Tokushi ^a   Chen, Zhe Sheng ^a,c   Che, Xiao Fang ^a   Matsumoto, Mitsugu ^a   Haraguchi, Misako ^a   Gotanda, Takenari ^a   Sumizawa, Tomoyuki ^a,d   Furukawa, Tatsuhiko ^a   Nishiyama, Kenryu ^a   Seki, Naohiko ^b   Yamamoto, Masatatsu ^a   Nakagawa, Masayuki ^a   Akiyama, Shin Ichi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Department of Pharmacy and Administrative Sciences   (United States)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

ABC transporters; Arsenite; Cisplatin; Drug resistance

Indexed keywords

ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SODIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL DIVISION; CELL MEMBRANE; CELL STRAIN KB; DNA PROBE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ARSENITES; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL MEMBRANE; DNA PROBES; DRUG RESISTANCE, NEOPLASM; HUMANS; KB CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM COMPOUNDS;

EID: 38449120734     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Zhu J, Chen Z, Lallemand-Breitenbach V and de The H: How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2: 705-713, 2002. (Pubitemid 37328921)
2. Wang Z, Rivi R, Delva L, et al: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92: 1497-1504, 1998. (Pubitemid 28406851)
3. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000. (Pubitemid 32110442)
4. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM and Zheng MH: Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 4: 33-37, 1999.
5. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-5440, 2001.
6. Kroemer G and de The H: Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 91: 743-745, 1999. (Pubitemid 29239052)
7. Larochette N, Decaudin D, Jacotot E, et al: Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 249: 413-421, 1999. (Pubitemid 29397949)
8. 3 - resistance in acute promyelocytic leukemia cells. Leukemia 17: 648-650, 2003.
9. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998. (Pubitemid 28509343)
10. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A and Fardel O: Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 61: 1387-1391, 2001. (Pubitemid 32452354)
11. Lee TC, Ko J and Jan KY: Differential cytotoxicity of sodium arsenite in human fibroblasts and Chinese hamster ovary cells. Toxicology 56: 289-299, 1989. (Pubitemid 19156631)
12. Aposhian HV: Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol 37: 397-419, 1997.
13. Zhao CQ, Young MR, Diwan BA, Coogan TP and Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94: 10907-10912, 1997. (Pubitemid 27430834)
14. Romach EH, Zhao CQ, Del Razo LM, Cebrian ME and Waalkes MP: Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol Sci 54: 500-508, 2000. (Pubitemid 30185973)
15. Liu J, Chen H, Miller DS, et al: Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60: 302-309, 2001. (Pubitemid 32678295)
16. Brambila EM, Achanzar WE, Qu W, Webber MM and Waalkes MP: Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione Stransferase. Toxicol Appl Pharmacol 183: 99-107, 2002. (Pubitemid 35286138)
17. Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000. (Pubitemid 30662093)
18. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
19. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006. (Pubitemid 43336035)
20. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
21. Mitsuhashi N, Miki T, Senbongi H, et al: MTABC3, a novel mitochondrial ATP-binding cassette protein involved in iron homeostasis. J Biol Chem 275: 17536-17540, 2000. (Pubitemid 30430795)
22. Liu SX, Athar M, Lippai I, Waldren C and Hei TK: Induction of oxyradicals by arsenic: Implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98: 1643-1648, 2001. (Pubitemid 32165551)
23. Shudo N, Mizoguchi T, Kiyosue T, et al: Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res 50: 3055-3061, 1990. (Pubitemid 20170762)
24. Sumizawa T, Chen ZS, Chuman Y, et al: Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51: 399-405, 1997. (Pubitemid 27118475)
25. 4 receptor antagonist, ONO-1078. Cancer Lett 130: 175-182, 1998.
26. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668, 2002. (Pubitemid 35424755)
27. Dalton WS: Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: Bahlis NJ et al: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668, 2002.
28. Watson RW, Redmond HP, Wang JH and Bouchier-Hayes D: Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. J Leukoc Biol 60: 625-632, 1996. (Pubitemid 26400420)
29. Ding W, Hudson LG and Liu KJ: Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol Cell Biochem 279: 105-112, 2005. (Pubitemid 43055148)
30. Morales A, Miranda M, Sanchez-Reyes A, Colell A, Biete A and Fernandez-Checa JC: Transcriptional regulation of the heavy subunit chain of -glutamylcysteine synthetase by ionizing radiation. FEBS Lett 427: 15-20, 1998. (Pubitemid 28210088)
31. Leslie EM, Haimeur A and Waalkes MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 279: 32700-32708, 2004. (Pubitemid 39014729)
32. Chen ZS, Aoki S, Komatsu M, et al: Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer 93: 107-113, 2001. (Pubitemid 32539509)
33. Lee TC, Ho IC, Lu WJ and Huang JD: Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem 281: 18401-18407, 2006.
34. Chen ZS, Kawabe T, Ono M, et al: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56: 1219-1228, 1999.